30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Pharmaceuticals

Organon & Co (OGN)

Track

Organon & Co. has seen recent insider buying activity, notably from its CEO and CFO. The stock has experienced significant positive price movement over the last 90 days. The last reported earnings showed a miss against expectations.
Stock chart
Ticker: OGN Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Holzbaur Lynette
Affiliate
1 buy, 1 sell — total 706,161 USD
Proposed sale 6 May 2026
Value US$3,474,031.90 | Price 357.42 | Shares 67,804
Buy 6 May 2026
Value US$4,929,741.22 | Price 391.71 | Shares 74,259
Buy 12 Nov 2025
Value US$2,338,638.39 | Price 183.12 | Shares 59,272
Buy 14 May 2025
Value US$100,591.16 | Price 8.07 | Shares 12,469
Buy 7 May 2025
Value US$48,235.00 | Price 8.77 | Shares 5,500
Buy 6 May 2025
Value US$74,054.22 | Price 9.21 | Shares 8,045
Buy 6 May 2025
Value US$28,828.10 | Price 8.24 | Shares 3,500
Buy 5 May 2025
Value US$100,548.00 | Price 8.82 | Shares 11,400
Buy 5 May 2025
Value US$299,370.00 | Price 8.81 | Shares 34,000
Buy 22 Feb 2024
Value US$49,938.93 | Price 18.36 | Shares 2,720
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-08 2026-05-06 PrS Proposed sale
Holzbaur Lynette

Affiliate
67,804
357.42
US$3,474,032 		67,804 357.42 US$3,474,032
2026-05-07 2026-05-06 B Purchase
Holzbaur Lynette

SVP and Corporate Controller

Officer
74,259 -13.1%
391.71
US$4,929,741 		74,259 -13.1% 391.71 US$4,929,741
2025-11-13 2025-11-12 B Purchase
2.8
COX CARRIE SMITH

Executive Chair

Executive Director
59,272 -32.3%
183.12
US$2,338,638 		59,272 -32.3% 183.12 US$2,338,638
2025-05-15 2025-05-14 B Purchase
2.8
COX CARRIE SMITH
Non-Executive Director
12,469 +inf%
8.07
US$100,591 		12,469 +inf% 8.07 US$100,591
2025-05-07 2025-05-07 B Purchase
2.4
Falcione Aaron

Chief Human Resources Officer

Officer
5,500 +9.6%
8.77
US$48,235 		5,500 +9.6% 8.77 US$48,235
2025-05-07 2025-05-06 B Purchase
3.1
Weaver Kirke

Gen. Counsel & Corp. Secy.

Officer
8,045 +18.1%
9.21
US$74,054 		8,045 +18.1% 9.21 US$74,054
2025-05-07 2025-05-06 B Purchase
3.1
Karp Daniel

Executive VP, Corp. Dev.

Officer
3,500 +8.1%
8.24
US$28,828 		3,500 +8.1% 8.24 US$28,828
2025-05-06 2025-05-05 B Purchase
1.8
WALSH MATTHEW M

Chief Financial Officer

Officer
11,400 +8.6%
8.82
US$100,548 		11,400 +8.6% 8.82 US$100,548
2025-05-06 2025-05-05 B Purchase
2.9
Ali Kevin

Chief Executive Officer

Executive Director
34,000 +13.7%
8.81
US$299,370 		34,000 +13.7% 8.81 US$299,370
2024-02-23 2024-02-22 B Purchase
3.1
Weaver Kirke

Gen. Counsel & Corp. Secy.

Officer
2,720 +21.8%
18.36
US$49,939 		2,720 +21.8% 18.36 US$49,939
Explore more

More insider trading research around Organon & Co

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America